These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17583372)

  • 21. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
    Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
    Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of a child having generalized Kaposi's sarcoma after living donor liver transplantation with conversion to sirolimus.
    Yuksekkaya HA; Arikan C; Yazici A; Baran M; Aydogdu S; Kilic M
    Pediatr Transplant; 2009 May; 13(3):375-8. PubMed ID: 18452496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kaposi's sarcoma resolves after sirolimus therapy in a patient with pemphigus vulgaris.
    Saggar S; Zeichner JA; Brown TT; Phelps RG; Cohen SR
    Arch Dermatol; 2008 May; 144(5):654-7. PubMed ID: 18490593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
    Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
    Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe psoriasis treated with a new macrolide: everolimus.
    Frigerio E; Colombo MD; Franchi C; Altomare A; Garutti C; Altomare GF
    Br J Dermatol; 2007 Feb; 156(2):372-4. PubMed ID: 17223881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment.
    Jozwiak J; Jozwiak S; Oldak M
    Med Res Rev; 2006 Mar; 26(2):160-80. PubMed ID: 16329102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sirolimus monotherapy in liver transplantation.
    Di Benedetto F; Di Sandro S; De Ruvo N; Masetti M; Montalti R; Romano A; Guerrini GP; Ballarin R; De Blasiis MG; Gerunda GE
    Transplant Proc; 2007; 39(6):1930-2. PubMed ID: 17692656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kaposi Sarcoma in the Era of Rapamycin Remains a Therapeutic Challenge in Organ Transplant Recipients.
    Tunçer Vural A; Karataş Toğral A; Güleç AT; Haberal M
    Exp Clin Transplant; 2018 Mar; 16 Suppl 1(Suppl 1):25-27. PubMed ID: 29527986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sirolimus in renal transplantation.
    Morath C; Arns W; Schwenger V; Mehrabi A; Fonouni H; Schmidt J; Zeier M
    Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapamycin and tuberous sclerosis complex: from Easter Island to epilepsy.
    Crino PB
    Ann Neurol; 2008 Apr; 63(4):415-7. PubMed ID: 18360828
    [No Abstract]   [Full Text] [Related]  

  • 31. Minimizing the risk of posttransplant malignancy.
    Campistol JM
    Transplant Proc; 2008 Dec; 40(10 Suppl):S40-3. PubMed ID: 19100906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The macrolide immunosuppressants in dermatology: mechanisms of action.
    Marsland AM; Griffiths CE
    Eur J Dermatol; 2002; 12(6):618-22. PubMed ID: 12459545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of mTOR inhibitors in the management of posttransplant malignancy.
    Monaco AP
    Transplantation; 2009 Jan; 87(2):157-63. PubMed ID: 19155967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass.
    Diekmann F; Rovira J; Carreras J; Arellano EM; Bañón-Maneus E; Ramírez-Bajo MJ; Gutiérrez-Dalmau A; Brunet M; Campistol JM
    J Am Soc Nephrol; 2007 Oct; 18(10):2653-60. PubMed ID: 17804674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of post-renal transplant gastric and pulmonary Kaposi's sarcoma with conversion to rapamycin treatment.
    Charfi S; Krichen-Makni S; Yaich S; Makni H; Khabir A; Amouri A; Charfeddine K; Hachicha J; Sellami-Boudawara T
    Saudi J Kidney Dis Transpl; 2007 Nov; 18(4):617-20. PubMed ID: 17951954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapamycin: something old, something new, sometimes borrowed and now renewed.
    Hartford CM; Ratain MJ
    Clin Pharmacol Ther; 2007 Oct; 82(4):381-8. PubMed ID: 17728765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports.
    Iaria G; Anselmo A; De Luca L; Manuelli M; Lucchesi C; Tariciotti L; Monaco A; Sforza D; Nigro F; Abruzzese E; Tisone G
    Transplant Proc; 2007; 39(6):2036-7. PubMed ID: 17692685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Azoospermia in a renal transplant recipient during sirolimus (rapamycin) treatment.
    Skrzypek J; Krause W
    Andrologia; 2007 Oct; 39(5):198-9. PubMed ID: 17714220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sirolimus therapy in liver transplant patients: an initial experience at a single center.
    Nocera A; Andorno E; Tagliamacco A; Morelli N; Bottino G; Ravazzoni F; Casaccia M; Barocci S; Alice S; Santori G; Ghirelli R; Valente U
    Transplant Proc; 2008; 40(6):1950-2. PubMed ID: 18675098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.